Bhap Der
Bhap Der - General Information
A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.
Pharmacology of Bhap Der
Bhap Der is a non-nucleoside reverse transcriptase inhibitor (nNRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Bhap Der binds directly to reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by causing a disruption of the enzyme's catalytic site. The activity of Bhap Der does not compete with template or nucleoside triphosphates. HIV-2 RT and eukaryotic DNA polymerases (such as human DNA polymerases alpha, beta, or sigma) are not inhibited by Bhap Der.
Bhap Der for patients
Patients should be informed that RESCRIPTOR is not a cure for HIV-1
infection and that they may continue to acquire illnesses associated
with HIV-1 infection, including opportunistic infections. Treatment
with RESCRIPTOR has not been shown to reduce the incidence or frequency
of such illnesses, and patients should be advised to remain under the
care of a physician when using RESCRIPTOR. Patients should be advised
that the long-term effects of treatment with RESCRIPTOR are unknown at
this time. They should be advised that the use of RESCRIPTOR has not been
shown to reduce the risk of transmission of HIV-1.
Bhap Der Interactions
Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir,
Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin,
Ritanovir, Saquinavir.
Bhap Der Contraindications
RESCRIPTOR Tablets are contraindicated in patients with previously
demonstrated clinically significant hypersensitivity to any of the
components of the formulation.
Additional information about Bhap Der
Bhap Der Indication: For the treatment of HIV-1 infection in combination with appropriate antiretroviral agents when therapy is warranted
Mechanism Of Action: Bhap Der binds directly to viral reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by disrupting the enzyme's catalytic site.
Drug Interactions: Alprazolam The antiviral agent increases the effect and toxicity of benzodiazepine
Amprenavir Decreased levels of delavirdine with increased levels of amprenavir
Astemizole Increased risk of cardiotoxicity and arrhythmias
Atorvastatin The NNRT inhibitor increases the effect and toxicity of the statin
Carbamazepine The anticonvulsant decreases the effect of delavirdine
Cisapride Increased risk of cardiotoxicity adn arrhythmias
Dihydroergotamine The antiretroviral agent may increase the ergot derivative toxicity
Dihydroergotoxine The antiretroviral agent may increase the ergot derivative toxicity
Ergonovine The antiretroviral agent may increase the ergot derivative toxicity
Ergotamine The antiretroviral agent may increase the ergot derivative toxicity
Fosamprenavir Decreased levels of delavirdine with increased levels of amprenavir
Fosphenytoin The anticonvulsant decreases the effect of delavirdine
Indinavir Increases the effect of indinavir
Lovastatin The NNRT inhibitor increases the effect and toxicity of the statin
Methylergonovine The antiretroviral agent may increase the ergot derivative toxicity
Methylphenobarbital The anticonvulsant decreases the effect of delavirdine
Methysergide The antiretroviral agent may increase the ergot derivative toxicity
Midazolam The antiviral agent increases the effect and toxicity of benzodiazepine
Phenobarbital The anticonvulsant decreases the effect of delavirdine
Phenytoin The anticonvulsant decreases the effect of delavirdine
Quinupristin This combination presents an increased risk of toxicity
Rifabutin Rifabutin decreases the effect of delavirdine
Rifampin Rifampin decreases the effect of delavirdine
Ritonavir Increases the effect of ritonavir
Saquinavir Increases the effect of saquinavir and hepatic toxicity
Simvastatin The NNRT inhibitor increases the effect and toxicity of the statin
St. John's Wort St. John's Wort decreases the antiretroviral effect
Terfenadine Increased risk of cardiotoxicity and arrhythmias
Triazolam The antiviral agent increases the effect and toxicity of benzodiazepine
Aluminium The antiacid decreases the effect of delavirdine
Bismuth The antiacid decreases the effect of delavirdine
Calcium The antiacid decreases the effect of delavirdine
Magnesium oxide The antiacid decreases the effect of delavirdine
Magnesium The antiacid decreases the effect of delavirdine
Food Interactions: Take without regard to meals.
Generic Name: Delavirdine
Synonyms: DLV; SPP
Drug Category: Anti-HIV Agents; Nonnucleoside Reverse Transcriptase Inhibitors
Drug Type: Small Molecule; Approved
Other Brand Names containing Delavirdine: Bhap Der; Rescriptor;
Absorption: Rapidly absorbed
Toxicity (Overdose): Major toxicity of delavirdine is rash and should be advised to promptly notify their physician should rash occur. The majority of rashes associated with delavirdine occur within 1 to 3 weeks after initiating treatment with delavirdine. The rash normally resolves in 3 to 14 days and may be treated symptomatically while therapy with delavirdine is continued. Any patient experiencing severe rash or rash accompanied by symptoms such as fever, blistering, oral lesions, conjunctivitis, swelling, muscle or joint aches should discontinue medication and consult a physician.
Protein Binding: 98%
Biotransformation: Hepatic
Half Life: 5.8 hours
Dosage Forms of Bhap Der: Tablet Oral
Chemical IUPAC Name: N-[2-[4-[3-(propan-2-ylamino)pyridin-2-yl]piperazine-1-carbonyl]-1H-indol-5-yl]methanesulfonamide
Chemical Formula: C22H28N6O3S
Delavirdine on Wikipedia: https://en.wikipedia.org/wiki/Delavirdine
Organisms Affected: Human Immunodeficiency Virus
